Causes of death of patients with non-valvular atrial fibrillation in Asians

被引:6
|
作者
Krittayaphong, Rungroj [1 ]
Boonyapiphat, Thanita [2 ]
Aroonsiriwattana, Suchart [3 ]
Ngamjanyaporn, Pornchai [4 ]
Lip, Gregory Y. H. [5 ,6 ,7 ]
机构
[1] Mahidol Univ, Siriraj Hosp, Dept Med, Div Cardiol,Fac Med, Bangkok, Thailand
[2] Lampang Hosp, Lampang, Thailand
[3] Surat Thani Hosp, Surat Thani, Thailand
[4] Chonburi Hosp, Chon Buri, Thailand
[5] Univ Liverpool, Liverpool John Moores Univ & Liverpool Heart, Liverpool Ctr Cardiovasc Sci, Liverpool, England
[6] Chest Hosp, Liverpool, England
[7] Aalborg Univ, Fac Med, Dept Clin Med, Aalborg, Denmark
来源
PLOS ONE | 2023年 / 18卷 / 03期
关键词
ANTAGONIST ORAL ANTICOAGULANTS; VITAMIN-K ANTAGONIST; STROKE PREVENTION; HEMORRHAGE; INSIGHTS; OUTCOMES; RISK;
D O I
10.1371/journal.pone.0282455
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
ObjectivesThe aim of this study was to determine the causes of death among Asian non-valvular atrial fibrillation (AF) patients who were registered in a nationwide AF registry, and to investigate the differences in the causes of death in AF patients compared between those who were taking and not taking oral anticoagulant (OAC). MethodsThe COhort of antithrombotic use and Optimal INR Level in patients with non-valvular Atrial Fibrillation in Thailand (COOL-AF) study enrolled non-valvular AF patients from 27 centers in Thailand during 2014-2017 to create the COOL-AF Thailand registry. Cause of death was classified as cardiovascular (CV) death, non-CV death, or undetermined cause of death. All events were evaluated and verified by an independent adjudication committee. ResultsThere was a total of 3,405 patients (mean age: 67.8 years, 41.8% female), and the mean follow-up duration was 31.8 +/- 8.7 months. Three hundred and eighty patients (11.2%) died during follow-up. CV death, non-CV death, and undetermined cause accounted for 121 (31.8%), 189 (49.7%), and 70 (18.4%) patients, respectively. Of those with a known cause of death, heart failure (10%), intracranial hemorrhage (ICH; 10%), sudden cardiac death (6.8%), and ischemic stroke (5.8%) were the most often observed causes of death. Concerning non-CV death, infection/sepsis (27.7%), cancer (5.5%), respiratory (5.2%), and major bleeding (4.5%) were the most prevalent causes of death. The use and type of OAC were found to be major determinants of ICH and major bleeding incidence. ConclusionDeath due to ischemic stroke was responsible for only 4.7% of all deaths in Asian AF patients. Non-CV death, such as infection/sepsis or malignancy, was more far more prevalent than CV death in Asian AF patients. An improved integrated care approach is needed to reduce the prevalence of non-CV death in Asian AF patients.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation
    Nissan, Ran
    Spectre, Galia
    Hershkovitz, Avital
    Green, Hefziba
    Shimony, Shai
    Cooper, Lisa
    Nakav, Sigal
    Shochat, Tzippy
    Grossman, Alon
    Fuchs, Shmuel
    DRUGS & AGING, 2019, 36 (02) : 165 - 177
  • [22] Cause of Stroke In Anticoagulated Patients with Non-Valvular Atrial Fibrillation
    Theodore, Wein
    Heather, Perkins
    Lisa, Wadup
    Lucy, Vieira
    Eric, Ehrensperger
    Jeffrey, Minuk
    Robert, Cote
    INTERNATIONAL JOURNAL OF STROKE, 2017, 12 : 7 - 8
  • [23] PHARMACOUTILIZATION IN PATIENTS SUFFERING FROM NON-VALVULAR ATRIAL FIBRILLATION
    Cataldo, N.
    Ripellino, C.
    Di Virgilio, R.
    De Solda, F.
    VALUE IN HEALTH, 2016, 19 (07) : A656 - A657
  • [24] Improving thromboprophylaxis in elderly patients with non-valvular atrial fibrillation
    Lowdon, DW
    Harper, JR
    Gillespie, ND
    SCOTTISH MEDICAL JOURNAL, 2004, 49 (04) : 148 - 150
  • [25] Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation
    Ran Nissan
    Galia Spectre
    Avital Hershkovitz
    Hefziba Green
    Shai Shimony
    Lisa Cooper
    Sigal Nakav
    Tzippy Shochat
    Alon Grossman
    Shmuel Fuchs
    Drugs & Aging, 2019, 36 : 165 - 177
  • [26] Renal function and outcome of patients with non-valvular atrial fibrillation
    Barashi, Rami
    Hornik-Lurie, Tzipi
    Gabay, Hagit
    Haskiah, Feras
    Minha, Saar
    Shuvy, Mony
    Assali, Abid
    Pereg, David
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2021, 10 (10) : 1180 - 1186
  • [27] Novel Anticoagulants for Non-valvular Atrial Fibrillation
    Xu, Bo
    Whitbourn, Robert
    HEART LUNG AND CIRCULATION, 2012, 21 (08): : 463 - 467
  • [28] Echocardiographic predictors of non-valvular atrial fibrillation
    David, C
    Almeida, A
    Marques, P
    Oliveira, EI
    Rodrigues, S
    Vagueiro, MC
    EUROPEAN HEART JOURNAL, 2003, 24 : 388 - 388
  • [29] Non-valvular atrial fibrillation and stroke prevention
    Hankey, GJ
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (05) : 234 - 239
  • [30] Newer Anticoagulants for Non-Valvular Atrial Fibrillation
    Harburger, Joseph M.
    Aronow, Wilbert S.
    PHARMACEUTICALS, 2012, 5 (05) : 469 - 480